Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Rating of “Buy” from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $129.43.

Several brokerages recently issued reports on LNTH. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Truist Financial upped their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Finally, The Goldman Sachs Group initiated coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,109 shares of company stock valued at $6,110,806. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after buying an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at about $323,000. Focus Financial Network Inc. purchased a new position in shares of Lantheus in the fourth quarter worth about $292,000. Finally, Harbor Capital Advisors Inc. grew its stake in Lantheus by 12.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock valued at $13,006,000 after acquiring an additional 16,466 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $96.16 on Friday. Lantheus has a fifty-two week low of $58.16 and a fifty-two week high of $126.89. The firm has a market capitalization of $6.59 billion, a PE ratio of 16.00 and a beta of 0.38. The stock’s 50-day simple moving average is $93.21 and its 200-day simple moving average is $96.42.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Sell-side analysts forecast that Lantheus will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.